Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates

Circulation

Volumn 96, Issue 3, 1997, Pages 941-948

  Sundell, I Birgitta ^a   Marzec, Ulla M ^a   Kelly, Andrew B ^a   Chronos, Nicolas A F ^a   Petersen, Lars C ^a,b   Hanson, Stephen R ^a   Hedner, Ulla ^a,b   Harker, Laurence A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Plasminogen; Plasminogen activators; Platelets; Thrombolysis

Indexed keywords

FIBRIN; HEPARIN; INDIUM 111; IODINE 125; PLASMINOGEN; RECOMBINANT LYSYL PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD VESSEL GRAFT; CONTROLLED STUDY; DISSOLUTION; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; STENT; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0030877546     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.941     Document Type: Article

References (58)

1. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation. 1990;82(suppl II):II-47-II-59.
2. Maseri A. Pathogenic components of acute ischemic syndromes. Circulation. 1990;81:1-3.
3. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:199-205.
4. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990; 322:33-42.
5. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
6. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell' infarto miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
7. ISIS Steering Committee. Intravenous streptokinase given within 0-4 hours of onset of myocardial infarction reduced mortality in ISIS-2. Lancet. 1987;1:502-510.
8. Chesebro JH, Knatterud G, Braunwald E. Thrombolytic therapy. N Engl J Med. 1988;319:1544-1545.
9. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
10. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
11. Lijnen HR, Nelles L, Van Hoef B, deCock F, Collen D. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains. J Biol Chem. 1990;265:5677-5683.
12. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 1989;339:721-724.
13. Jang I, Gold HK, Leinbach RC, McNary JE, Fallon JT, Collen D. Acceleration of reperfusion by combination of rt-PA and a selective thrombin inhibitor, argatroban. Circulation. 1989;80(suppl II): II-217. Abstract.
14. Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, Loscalzo J. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ Res. 1992;70:829-834.
15. Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation. 1991;83:1038-1047.
16. Collen D, Lijnen HR, Verstraete M. Fibrinolytic system and its disorders. In: Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. Philadelphia, Pa: JB Lippincott; 1995: 1261-1288.
17. Suenson E, Thorsen S. The course and prerequisites for Lys-plasminogen formation during fibrinolysis. Biochemistry. 1988;27: 2435-2443.
18. Fredenburg JC, Nesheim ME. Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro. J Biol Chem. 1992;267:26150-26159.
19. Badylak SF, Voytik SL, Henkin J, Burke S, Sasahara AA, Simmons A. The beneficial effect of Lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis. Haemostasis. 1991;21:278-285.
20. Chen LY, Mehta JL. Lys- and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation. Thromb Res. 1994;74:555-563.
21. Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengard C, Hedner U, Saldeen TG. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs. J Am Coll Cardiol. 1995;25:753-760.
22. Busby SJ, Mulvihill E, Rao D. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity. J Biol Chem. 1991;266:15286-15292.
23. Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Caban R, Shaw S-Y, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. 1996;94:1412-1422.
24. 111Indium-labeled platelets in baboons. Blood. 1986;68:386-393.
25. Harker LA, Hanson SR, Kirkman TR. Experimental arterial thromboembolism in baboons: mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979;64:559-569.
26. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone. Proc Natl Acad Sci U S A. 1988;85: 3184-3188.
27. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood. 1991;77:1006-1012.
28. Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts: a model of acute thrombosis in baboons. Arteriosclerosis. 1985;5:595-603.
29. Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990;82:578-585.
30. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970;170:1095-1096.
31. Harker LA, Kelly AB, Hanson SR. Experimental arterial thrombosis in non-human primates. Circulation. 1991;83(suppl IV): IV-41-IV-55.
32. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, Harker LA. Effects of angiotensin converting enzyme inhibition with cilazapril on intimai hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991; 18(suppl II):II-70-II-76.
33. Krupski WC, Bass A, Kelly AB, Hanson SR, Harker LA. Reduction in thrombus formation by placement of endovascular stents at endarterectomy sites in baboon carotid arteries. Circulation. 1991; 84:1749-1757.
34. Lumsden AB, Kelly AB, Schneider PA, Krupski WC, Dodson T, Hanson SR, Harker LA. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood. 1993;81:1762-1770.
35. Hanson SR, Pareti FI, Ruggeri ZM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest. 1988;81:149-158.
36. Hanson SR, Harker LA, Bjornsson TD. Effects of platelet-modifying drugs on arterial thromboembolism in baboons: aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest. 1985;75:1591-1599.
37. Harker LA, Kelly AB, Hanson SR, Krupski W, Bass A, Osterud B, FitzGerald GA, Goodnight SH, Connor WE. Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation. 1993;87:1017-1029.
38. Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in non-human primates. Blood. 1994;83:3218-3224.
39. Hanson SR, Wilcox JN, Kelly AB, Lumsden AB, Scott NA, Harker LA. Thrombin mediation of arterial smooth muscle cell (SMC) proliferation after mechanical vascular injury in non-human primates. Blood. 1992;80(suppl I):166a. Abstract.
40. Kelly AB, Hanson SR, Dunwiddie CT, Harker LA. Safe lasting interruption of arterial thrombosis by transient intravenous administration of tick anticoagulant peptide (TAP). Circulation. 1992; 86(suppl I):I-411. Abstract.
41. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972;287:155-159.
42. Harker LA, Malpass TW, Branson HE, Hessel I, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha granule release. Blood. 1980;56:824-834.
43. Malpass TW, Hanson SR, Savage B, Hessel EA, Harker LA. Prevention of acquired transient defect in platelet plug formation by infused prostacyclin. Blood. 1981;57:736-740.
44. Cadroy Y, Hanson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost. 1993;70:631-635.
45. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation. 1995;92:485-491.
46. Weisel JW, Nagaswami C, Korsholm B, Petersen LC, Suenson E. Interactions of plasminogen with polymerizing fibrin and its derivatives, monitored with a photoaffinity cross-linker and electron microscopy. J Mol Biol. 1994;235:1117-1135.
47. Petersen LC, Suenson E. Effect of plasminogen and tissue-type plasminogen activator on fibrin gel structure. Fibrinolysis. 1991;5: 51-59.
48. Garman AM, Smith RAG. The binding of plasminogen to fibrin: evidence for plasminogen-bridging. Thromb Res. 1982;27:311-320.
49. Carr ME, Shen LL, Hermans J. Mass-length ratio of fibrin filters from gel permeation and light scattering. Biopolymers. 1977;16:1-15.
50. Carr ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules. 1978;11:46-50.
51. Suenson E, Thorsen S. Secondary site binding of glu-plasminogen, lys-plasminogen and miniplasmin to fibrin. Biochem J. 1981;197: 619-628.
52. Suenson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 1984;140:513-522.
53. Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med. 1980;96:985-993.
54. Aberg M, Hedner U, Bergentz S-E. The antithrombotic effect of dextran. Scand J Haemost. 1979;34(suppl):61-68.
55. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation. 1992;85: 1706-1712.
56. Niewiarowski S, Senyi AF, Gilles P. Plasmin induced platelet aggregation and platelet release reaction. J Clin Invest. 1973;52: 1647-1659.
57. Lu H, Soria C, Li H, Soria J, Lijnen HR, Perrot JY, Caen JP. Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation. Thromb Haemost. 1991;65:67-72.
58. Stricker RB, Wong D, Shiu DT, Reyes PT, Sherman M. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood. 1986;68:275-280.